Oruka Therapeutics director granted 9,136 options

Oruka Therapeutics director Martin Christopher Nathan received a grant of stock options for 9,136 shares of common stock.

Rhea-AI Filing Summary

Oruka Therapeutics director Martin Christopher Nathan received a grant of stock options for 9,136 shares of common stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The award vests in equal monthly installments over 12 months starting June 2, 2026, aligning the director’s compensation with future company performance.

Insider Trade Summary

Grant/Award: 9,136 shares

Grant/Award 1 txn

Insider Martin Christopher Nathan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	9,136	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 9,136 contracts (Direct)

Footnotes (1)

1. F1. The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

Key Figures

Option grant size: 9,136 shares Exercise price: $55.23 per share Expiration date: June 1, 2036 +2 more

5 metrics

Option grant size 9,136 shares Underlying common stock for new stock option award

Exercise price $55.23 per share Strike price for the stock options

Expiration date June 1, 2036 Option term end for the grant

Post-transaction derivative holdings 9,136 options Total derivative securities following the grant

Vesting schedule 1/12 monthly Vests monthly from June 2, 2026 over 12 months

Key Terms

Stock Option (right to buy), exercise price, expiration date, Common Stock, +2 more

6 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "55.2300" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vests financial

"The option vests as to 1/12 of the underlying shares monthly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oruka Therapeutics (ORKA) report for Martin Christopher Nathan?

Oruka Therapeutics reported that director Martin Christopher Nathan received a grant of stock options for 9,136 shares. These options are a compensation award, not an open‑market purchase, and give him the right to buy common stock at a fixed exercise price.

How many Oruka Therapeutics (ORKA) shares are covered by the new stock options?

The new stock option grant covers 9,136 underlying shares of Oruka Therapeutics common stock. This entire amount reflects a single award, and Nathan’s total derivative holdings reported after the transaction are also 9,136 option-based shares.

What is the exercise price of Martin Christopher Nathan’s Oruka Therapeutics (ORKA) stock options?

The stock options granted to Martin Christopher Nathan carry an exercise price of $55.23 per share. This means he can choose to buy Oruka Therapeutics common stock at $55.23, regardless of the market price, once the options are vested and exercisable.

When do the newly granted Oruka Therapeutics (ORKA) stock options expire?

The stock options granted to Martin Christopher Nathan expire on June 1, 2036. After this expiration date, any unexercised portion of the 9,136-share award will lapse, and he will no longer have the right to purchase shares under this specific option grant.

How do Martin Christopher Nathan’s Oruka Therapeutics (ORKA) options vest over time?

The option grant vests as to one-twelfth of the underlying 9,136 shares each month starting June 2, 2026. This monthly vesting schedule spreads the award over 12 months, gradually increasing the portion of options that can be exercised over that period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin Christopher Nathan

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$55.23	06/02/2026		A		9,136		(1)	06/01/2036	Common Stock	9,136	$0	9,136	D

Explanation of Responses:

1. The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

	/s/ Paul Quinlan, as attorney-in-fact for Christopher Martin	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)